Glepaglutide is under clinical development by Zealand Pharma and currently in Phase III for Short Bowel Syndrome. According to GlobalData, Phase III drugs for Short Bowel Syndrome have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Glepaglutide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Glepaglutide (ZP-1848) is under development for the treatment of short bowel syndrome (SBS). ZP1848 is a long acting SIP-modified glucagon-like peptide-2 (GLP-2) analogue. It is administered as a solution through subcutaneous route. It is developed based on SIP technology. The SIP-technology is a protein modification technology. It was also under development for the treatment of Crohn’s disease.
Zealand Pharma overview
Zealand Pharma (Zealand) is a biotechnology company. It discovers, designs and develops peptide-based medicines that target specialty diseases. The company’s product portfolio comprises glepaglutide which is a long-acting GLP-2 analog in development for the treatment of short bowel syndrome and dasiglucagon is used against type 1 diabetes and congenital hyperinsulinism. It also offers GLP1-GLU which is used against several cardio-metabolic diseases such as heart disease, ischemic stroke and liver diseases. Zealand conducts research and development and in-licensing programs. It has operations in Denmark and the US. ealand is headquartered in Soeborg, Denmark.
For a complete picture of Glepaglutide’s drug-specific PTSR and LoA scores, buy the report here.